Latest Ratios: P/E Ratio 42.6x · EV/EBITDA 38.4x · ROE -18.2%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $455M | $345M | $112M | $71M | $108M | $171M | $128M | $39M | — |
| Enterprise Value | $1.8B | $460M | $360M | $96M | $61M | $100M | $157M | $120M | $13M | — |
| P/E Ratio → | 42.62 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.40 | 5.69 | 8.84 | 3.55 | 3.34 | 4.95 | 4379.78 | 133.35 | — | — |
| P/B Ratio | 65.72 | 17.40 | 14.12 | 7.26 | 5.42 | 6.13 | 10.91 | 12.12 | 1.49 | — |
| P/FCF | 45.79 | 44.65 | 365.77 | 18.60 | 34.88 | — | — | — | — | — |
| P/OCF | 166.27 | 43.24 | 355.96 | 16.48 | 14.71 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.75 | 9.23 | 3.04 | 2.88 | 4.60 | 4016.88 | 125.52 | — | — |
| EV / EBITDA | 38.43 | 111.78 | — | — | — | — | — | — | — | — |
| EV / EBIT | 9999.00 | 2063.19 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 45.15 | 381.74 | 15.95 | 30.07 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 53.5% | 60.0% | 66.6% | 67.4% | 88.0% | -633.3% | 52.8% | — | — |
| Operating Margin | 0.1% | 0.1% | -6.7% | -3.8% | -38.9% | -6.8% | -69515.4% | -1939.6% | — | — |
| Net Profit Margin | -5.8% | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | -71717.9% | -1910.3% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -18.2% | -18.2% | -19.2% | -6.6% | -58.8% | -11.7% | -213.4% | -99.4% | -66.3% | -59.0% |
| ROA | -5.5% | -5.5% | -7.1% | -3.3% | -34.4% | -7.3% | -128.9% | -80.7% | -61.0% | -53.2% |
| ROIC | 0.2% | 0.2% | -10.0% | -64.1% | -93.8% | -19.6% | -893.2% | -1068.6% | — | — |
| ROCE | 0.1% | 0.1% | -7.2% | -7.0% | -39.8% | -6.6% | -144.1% | -89.8% | -53.0% | -56.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 1.19 | 1.23 | 0.35 | 0.50 | 0.38 | 0.46 | 0.43 | — | — |
| Debt / EBITDA | 7.54 | 7.54 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.19 | 0.62 | -1.03 | -0.75 | -0.44 | -0.90 | -0.71 | -1.02 | -1.08 |
| Net Debt / EBITDA | 1.23 | 1.23 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 0.50 | 15.97 | -2.65 | -4.81 | — | — | — | — | — |
| Interest Coverage | 0.05 | 0.05 | -0.90 | -0.65 | -9.45 | -1.88 | -30.50 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.57 | 2.06 | 1.65 | 3.10 | 5.18 | 6.51 | 7.65 | 13.59 | 16.76 |
| Quick Ratio | 1.17 | 1.17 | 1.29 | 1.60 | 3.01 | 5.06 | 6.18 | 7.45 | 13.59 | 16.76 |
| Cash Ratio | 0.67 | 0.67 | 0.75 | 1.32 | 2.52 | 3.16 | 5.61 | 6.15 | 13.21 | 16.59 |
| Asset Turnover | — | 0.87 | 0.51 | 1.00 | 0.85 | 0.79 | 0.00 | 0.06 | — | — |
| Inventory Turnover | 2.41 | 2.41 | 1.02 | 11.61 | 12.45 | 4.77 | 0.23 | 1.19 | — | — |
| Days Sales Outstanding | — | 53.67 | 50.16 | 39.35 | 31.81 | 91.47 | 449.23 | 180.03 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 2.7% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 2.2% | 2.2% | 0.3% | 5.4% | 2.9% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.7% | — |
| Shares Outstanding | — | $27M | $26M | $26M | $25M | $25M | $21M | $18M | $6M | $17M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc.'s current P/E ratio is 42.6x. This places it at the 50th percentile of its historical range.
Eton Pharmaceuticals, Inc.'s current EV/EBITDA is 38.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Eton Pharmaceuticals, Inc.'s return on equity (ROE) is -18.2%. The historical average is -61.4%.
Based on historical data, Eton Pharmaceuticals, Inc. is trading at a P/E of 42.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Eton Pharmaceuticals, Inc. has 53.5% gross margin and 0.1% operating margin.
Eton Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 7.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Thin margins and leverage
Metrics are mathematically derived from official filings.
Premium Multiples Price in Sustained Growth
Based on reported figures, ETON trades at 37.67x trailing earnings, 33.98x EV/EBITDA, and 10.96x sales, multiples that imply investors are pricing in a durable scale-up of the orphan portfolio rather than current earnings power. These levels sit well above what a near-breakeven specialty pharma would normally command.
The forward P/E of 51.95 exceeds the trailing multiple, which suggests the market expects earnings to lag near-term revenue growth or that forward estimates are being revised downward, a pattern that warrants monitoring. A price-to-book of 58.09 reflects an equity base that is small relative to market value and is largely built from recent earnings rather than tangible capital. Investors should treat these multiples as contingent on margin conversion, since the trailing net margin of -5.8% offers little support for a multiple of this magnitude.
Margin Rebuild Outpaces Earnings Conversion
As reported in financial statements, ETON's gross margin rose from 35.0% in 2025Q3 to 76.5% in 2026Q3, yet trailing net margin remains -5.8%, showing that top-line gains have not yet translated into sustained bottom-line profitability.
The gross margin rebuild suggests a meaningful shift toward higher-value products and better unit economics, but operating margin of 39.7% in the latest quarter compares with a near-zero trailing operating margin of 0.1%, indicating the recent quarterly improvement is concentrated and not yet proven recurring. The gap between gross and net margin implies that operating expenses and below-the-line items continue to absorb most of the gross profit. Earnings quality should be judged on whether the latest quarter's margin level holds over several subsequent periods.
Returns Turn Positive But Remain Unproven
Based on ETON's reported figures, ROE moved from -10.7% in 2025Q2 to 52.8% in 2026Q3, while trailing ROE stands at -18.2%, so the recent swing reflects a few strong quarters against a longer negative base.
The jump in quarterly ROE to 52.8% is substantially inflated by a small equity base and a single strong earnings period, which limits its usefulness as a measure of durable capital efficiency. ROIC of 33.2% in the latest quarter compares with negative returns in 2025, suggesting the company may be moving from value destruction toward value creation, though this conclusion requires several more quarters to confirm. Investors should compare these figures against a sustained run of positive ROIC before treating the inflection as structural.
Debt Service Comfort Improves With Earnings
According to recent reported filings, ETON's debt-to-equity fell to 0.28 in 2026Q3 from 0.62 a quarter earlier, while interest coverage rose to 24.31x, indicating debt service has become considerably more comfortable as earnings recovered.
Total debt of $24.1M against a rebuilt equity base of $86.9M reduces the risk that interest obligations crowd out operations, and the coverage ratio suggests current earnings can absorb debt costs many times over. However, coverage was negative in several earlier quarters, so the improvement is recent and depends on operating income holding. Refinancing exposure and covenant terms are not detailed in the supplied data, so this assessment is limited to the reported ratios.
Cash Buffer Rebuilt Through Recent Inflows
As reported in financial statements, ETON's current ratio of 1.79 and quick ratio of 1.58 in 2026Q3 reflect a cash position of $55.6M, up from $19.7M in 2026Q1, indicating a liquidity buffer that has strengthened meaningfully within two quarters.
The quick ratio sitting close to the current ratio suggests inventory is a modest share of current assets, which lowers dependence on inventory conversion under stress. The rapid cash rebuild appears driven by operating inflows and working capital timing rather than external financing, though the reported data does not fully isolate these sources. Under a severe demand shock, the current cash balance would cover several quarters of the recent operating burn levels, but sustained profitability would still be needed for the buffer to grow.
Working Capital Cycle Compresses Sharply
Based on EDBL's reported figures, ETON's cash conversion cycle narrowed from 207 days in 2025Q2 to 8 days in 2026Q3, driven by falling inventory days from 243 to 72 and receivable days from 74 to 41.
The compression in inventory days suggests tighter production planning or faster wholesaler sell-through, which reduces the cash tied up in working capital. Payable days of 104 are high relative to receivable days, indicating the company is leaning on supplier credit to fund operations, a dependence that could reverse if vendors tighten terms. Investors should monitor whether the short cycle persists as revenue scales, since a return to earlier inventory levels would reintroduce meaningful cash drag.
Misapplied Gross Margin Obscures Net Economics
The most commonly misapplied ratio for this business is the quarterly gross margin of 76.5%, which appears to overstate earning power because gross-to-net adjustments, royalties, and launch timing are not reflected in the headline figure.
For a specialty pharma company operating under a 505(b)(2) model with orphan indications, gross margin can be inflated by revenue recognized before rebates, chargebacks, and co-pay programs are fully netted, and by milestone or licensing receipts that do not recur. A more reliable measure is net income adjusted for non-recurring items, or cash-based earnings power such as free cash flow margin across multiple quarters. The trailing net margin of -5.8% and ROE of -18.2% suggest that gross margin alone should not anchor a valuation view.